| Publications | PubMed=1906341; DOI=10.1002/gcc.2870030111
Glover T.W., Stein C.K., Legius E., Andersen L.B., Brereton A., Johnson S.
Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis.
Genes Chromosomes Cancer 3:62-70(1991) PubMed=1568246; DOI=10.1016/0092-8674(92)90407-4
DeClue J.E., Papageorge A.G., Fletcher J.A., Diehl S.R., Ratner N., Vass W.C., Lowy D.R.
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis.
Cell 69:265-273(1992) PubMed=7627966
Yan N., Ricca C.S., Fletcher J.A., Glover T.W., Seizinger B.R., Manne V.
Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Cancer Res. 55:3569-3575(1995) PubMed=9766530; DOI=10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9
Badache A., de Vries G.H.
Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB.
J. Cell. Physiol. 177:334-342(1998) PubMed=10791998; DOI=10.1172/JCI7610
DeClue J.E., Heffelfinger S.C., Benvenuto G., Ling B., Li S.-W., Rui W., Vass W.C., Viskochil D., Ratner N.
Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models.
J. Clin. Invest. 105:1233-1241(2000) PubMed=16239399; DOI=10.1124/jpet.105.091454
Mattingly R.R., Kraniak J.M., Dilworth J.T., Mathieu P., Bealmear B., Nowak J.E., Benjamins J.A., Tainsky M.A., Reiners J.J. Jr.
The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.
J. Pharmacol. Exp. Ther. 316:456-465(2006) PubMed=16510576; DOI=10.1158/0008-5472.CAN-05-3330
Miller S.J., Rangwala F., Williams J., Ackerman P., Kong S., Jegga A.G., Kaiser S., Aronow B.J., Frahm S., Kluwe L., Mautner V.-F., Upadhyaya M., Muir D.F. IV, Wallace M.R., Hagen J., Quelle D.E., Watson M.A., Perry A., Gutmann D.H., Ratner N.
Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
Cancer Res. 66:2584-2591(2006) PubMed=18650488; DOI=10.1215/15228517-2008-053
Holtkamp N., Malzer E., Zietsch J., Okuducu A.F., Mucha J., Mawrin C., Mautner V.-F., Schildhaus H.-U., von Deimling A.
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
Neuro-oncol. 10:946-957(2008) PubMed=21084276; DOI=10.1158/0008-5472.CAN-10-2799
Lopez G., Torres K.E., Liu J.J.-H., Hernandez B., Young E.D., Belousov R., Bolshakov S.V., Lazar A.J.F., Slopis J.M., McCutcheon I.E., McConkey D.J., Lev D.C.
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Cancer Res. 71:185-196(2011) PubMed=22346343; DOI=10.4137/TOG.S8830
Sun D., Tainsky M.A., Haddad R.
Oncogene mutation survey in MPNST cell lines enhances the dominant role of hyperactive Ras in NF1 associated pro-survival and malignancy.
Transl. Oncogenomics 5:1-7(2012) PubMed=23437333; DOI=10.1371/journal.pone.0057152
Reuss D.E., Mucha J., Hagenlocher C., Ehemann V., Kluwe L., Mautner V.-F., von Deimling A.
Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
PLoS ONE 8:E57152-E57152(2013) PubMed=24726063; DOI=10.1186/1756-9966-33-33
Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B., Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R., Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014) PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015) PubMed=28469964
Guo J.-M., Grovola M.R., Xie H., Coggins G.E., Duggan P., Hasan R., Huang J.-L., Lin D.W., Song C., Witek G.M., Berritt S., Schultz D.C., Field J.
Comprehensive pharmacological profiling of neurofibromatosis cell lines.
Am. J. Cancer Res. 7:923-934(2017) PubMed=28556483; DOI=10.1002/1878-0261.12086
Kolberg M., Bruun J., Murumagi A., Mpindi J.P., Bergsland C.H., Holand M., Eilertsen I.A., Danielsen S.A., Kallioniemi O.-P., Lothe R.A.
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Mol. Oncol. 11:1156-1171(2017) PubMed=32642732; DOI=10.1093/noajnl/vdz049
Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.
Genetics of human malignant peripheral nerve sheath tumors.
Neurooncol. Adv. 2:I50-I61(2020) |
|---|